Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

Breast Cancer Clinical Trial

Official title:

Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00681369
• Other study ID #: NIS-OFR-FAS-2007/1
• Status: Completed
• Phase: N/A
• First received: May 20, 2008
• Last updated: January 21, 2011
• Start date: May 2007
• Est. completion date: June 2007

Study information

• Verified date: January 2011
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Haute Autorité de Santé Transparency Commission
• Study type: Observational

Clinical Trial Summary

the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile

Recruitment information / eligibility

• Status: Completed
• Enrollment: 217
• Est. completion date: June 2007
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluate Faslodex therapeutic strategy and treatment duration		At the end of the study	No
Primary	Describe the characteristics of patients treated with Faslodex		At the end of the study	No